Teva Pharmaceutical Industries (TEVA) Leases (2018 - 2026)

Teva Pharmaceutical Industries has disclosed Leases across 9 years of filings, most recently posting $335.0 million for Q1 2026.

• Quarterly Leases fell 7.71% year-over-year to $335.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $335.0 million (down 7.71% YoY) and the FY2025 annual result came in at $345.0 million, down 5.99% from the prior year.
• Leases eased to $335.0 million in Q1 2026, from $345.0 million in the prior quarter.
• Over five years, Leases peaked at $464.0 million in Q1 2022 and troughed at $335.0 million in Q1 2026.
• A 5-year average of $387.2 million and a median of $367.0 million in 2024 frame the typical range for Leases.
• Annual changes were most pronounced in 2022 — Leases declined 16.95% — and 2025, when it changed 0.0%.
• Tracing TEVA's Leases over 5 years: stood at $419.0 million in 2022, then decreased by 5.25% to $397.0 million in 2023, then fell by 7.56% to $367.0 million in 2024, then dropped by 5.99% to $345.0 million in 2025, then fell by 2.9% to $335.0 million in 2026.
• Business Quant data shows TEVA's Leases at $335.0 million in Q1 2026, $345.0 million in Q4 2025, and $342.0 million in Q3 2025.